Takeda Pharmaceutical Company Limited Profit Loss Attributable To Ordinary Equity Holders Of Parent Entity Including Dilutive Effects
Takeda Pharmaceutical Company Limited (TKPHF) reported Profit Loss Attributable To Ordinary Equity Holders Of Parent Entity Including Dilutive Effects of JPY 107.93 billion for the 12-month period ending 2025-03-31, per its 20-F filed 2025-06-25.
Financial Statements › Income Statement › Earnings Per Share
ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityIncludingDilutiveEffects · last filed 2025-06-25
| Period end | Profit Loss Attributable To Ordinary Equity Holders Of Parent Entity Including Dilutive Effects 12 month | Profit Loss Attributable To Ordinary Equity Holders Of Parent Entity Including Dilutive Effects 12 month as first filed |
|---|---|---|
| 2025-03-31 | 107.93B JPY 20-F · filed 2025-06-25 | |
| 2024-03-31 | 144.07B JPY 20-F · filed 2025-06-25 | |
| 2023-03-31 | 317.02B JPY 20-F · filed 2025-06-25 | |
| 2022-03-31 | 230.06B JPY 20-F · filed 2024-06-26 | |
| 2021-03-31 | 376.00B JPY 20-F · filed 2023-06-28 | |
| 2020-03-31 | 44.24B JPY 20-F · filed 2022-06-29 | |
| 2019-03-31 | 135.19B JPY 20-F · filed 2021-06-29 | 109.13B JPY 20-F · filed 2019-06-27 |
| 2018-03-31 | 186.89B JPY 20-F · filed 2020-06-24 | |
| 2017-03-31 | 114.94B JPY 20-F · filed 2019-06-27 |